CommercialCoverageMedium impact
06.02.30f, Pharmacogenetic Testing to Determine Drug Sensitivity (Independence Administrators)
Independence Blue Cross·Family Medicine, Internal Medicine, Cardiology +4 more·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued their pharmacogenetic testing policy (06.02.30f) for determining drug sensitivity. This is a policy reissuance that became effective October 1, 2025, affecting commercial plans.
Action Required
By October 1, 2025: Billing team should review the updated pharmacogenetic testing policy on the Independence Administrators website to understand any changes in coverage criteria or billing requirements for drug sensitivity testing. Verify current billing practices align with reissued policy requirements.